SCWorx Corp. Announces Nasdaq Hearings Panel Grants Request for Reconsideration and Approves Continued Listing on The Nasdaq Capital Market

Continued listing carries one year of monitoring, with no cure period for a listing-standard failure during that period.

Rhea-AI Summary

SCWorx (WORX) won approval on October 2, 2026, to continue its Nasdaq Capital Market listing after the Hearings Panel reconsidered its delisting decision. The Panel found compliance with continued listing requirements, including minimum bid price and publicly held shares. Nasdaq trading, suspended since April 14, 2026, will resume on a date Nasdaq sets; shares remain quoted on OTCQB until then.

A September 16 private placement and warrant exercises increased publicly held shares to 549,092 as of September 17, above the 500,000-share minimum. Closing bids have remained at least $1.00 since August 4, 2026. Placement investors agreed not to terminate their purchases based on the September 17 delisting decision. Continued listing includes a one-year monitoring period ending October 2, 2027 and monthly share reports through October 5, 2027. Any listing-standard failure during monitoring would trigger a delisting determination without a compliance plan or cure period.

4 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointOctober 2, 2026 Panel approval permits continued Nasdaq Capital Market listing after reconsideration of the delisting decision.
• Minor point549,092 publicly held shares as of September 17, 2026 exceeded Nasdaq’s 500,000-share minimum.
• Minor pointClosing bid price of at least $1.00 persisted every trading day since August 4, 2026.
• Minor pointAll September 2026 placement investors delivered agreements not to terminate purchases based on the September 17 decision.

Negative

• Moderate pointNasdaq trading remains suspended pending a Nasdaq-scheduled reinstatement date; OTCQB quotations continue meanwhile.
• Moderate pointPrivate placement and warrant exercises added shares, diluting existing holders.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Panel monitoring through October 2, 2027 removes compliance-plan and cure-period options for any continued-listing failure.
• Minor pointMonthly reports through October 5, 2027 must disclose outstanding shares, insider holdings and public float to Nasdaq.

Key Figures

Publicly held shares: 549,092 shares vs. 500,000-share minimum Minimum bid price: $1.00 per share Bid-price compliance period: 10 consecutive trading days +2 more

Publicly held shares

549,092 shares vs. 500,000-share minimum

As of September 17, 2026; Nasdaq continued-listing requirement

Minimum bid price

$1.00 per share

Nasdaq Listing Rule 5550(a)(2)

Bid-price compliance period

10 consecutive trading days

Required following September 17, 2026

Panel monitor

One year, ending October 2, 2027

Condition of continued listing

Monthly reports to Nasdaq

Through October 5, 2027

Reports cover shares outstanding, insider holdings and public float

Historical Context

3 past events · Latest: Jun 23

3 events

1. Jun 23

   Nasdaq listing decision

   24h Move

   +115.5%

   Panel allowed continued listing subject to conditions, including regaining the minimum bid price.

2. Jul 29

   Partial compliance letter

   24h Move

   +1.6%

   Panel confirmed the first compliance-plan benchmark, while the minimum bid-price condition remained.

3. Sep 17

   Equity financing

   24h Move

   -2.2%

   Private placement and warrant exercises supported the publicly held shares requirement; investors had repayment rights under specified conditions.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, warrants, public float, form 8-k

4 terms

private placement financial

"The Panel's decision followed the Company's September 16, 2026 private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

warrants financial

"which, together with the exercise of outstanding warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

public float financial

"monthly reports of its shares outstanding, insider holdings and public float"

Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.

form 8-k regulatory

"set forth in the Company's Current Report on Form 8-K filed with the Securities"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Panel Determines Company Has Regained Compliance With Nasdaq Continued Listing Requirements; Trading on Nasdaq to Be Reinstated on a Date to Be Set by Nasdaq

MIDDLETON, Mass, Oct. 05, 2026 (GLOBE NEWSWIRE) --  SCWorx Corp. (OTCQB: WORX) (the "Company"), a provider of data management solutions to healthcare providers, today announced that on October 2, 2026, the Nasdaq Hearings Panel (the "Panel") granted the Company's request for reconsideration of the Panel's September 17, 2026 decision to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq"). In its October 2, 2026 decision, the Panel determined that the Company now demonstrates compliance with the continued listing requirements of Nasdaq, including the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) and the minimum publicly held shares requirement of Nasdaq Listing Rule 5550(a)(4), and granted the Company's request for continued listing on The Nasdaq Capital Market, subject to the conditions described below.

Trading in the Company's common stock on Nasdaq, which has been suspended since April 14, 2026, will be reinstated on a date to be scheduled by Nasdaq. The Company is submitting Nasdaq's reinstatement form today and expects to announce the reinstatement date once it is confirmed by Nasdaq. Until trading on Nasdaq is reinstated, the Company's common stock will continue to be quoted on the OTCQB Venture Market under the symbol "WORX."

The Panel's decision followed the Company's September 16, 2026 private placement, which, together with the exercise of outstanding warrants, increased the Company's publicly held shares to 549,092 shares as of September 17, 2026, above the 500,000-share minimum required by Nasdaq Listing Rule 5550(a)(4). On September 30, 2026, the Nasdaq Listing Qualifications Staff confirmed that the Company had regained compliance with the publicly held shares requirement as of September 17, 2026. The Company's closing bid price has been at or above $1.00 per share on every trading day since August 4, 2026, including the 10 consecutive trading days following September 17, 2026 required under Nasdaq Listing Rule 5810(c)(3)(A).

"We are pleased that the Panel has recognized the steps the Company has taken to regain compliance with Nasdaq's listing requirements and look forward to the resumption of trading on Nasdaq," said Tim Hannibal, CEO of SCWorx.

As a condition of continued listing, the Panel required the Company to publicly disclose that each investor in the September 2026 private placement has agreed that it will not exercise its contractual right under the securities purchase agreement to terminate its purchase based on the Panel's September 17, 2026 decision. Each of the investors has delivered that agreement to the Company. The Panel also imposed a Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A) for a one-year period ending October 2, 2027, and required the Company to provide monthly reports of its shares outstanding, insider holdings and public float to Nasdaq through October 5, 2027. If Nasdaq determines that the Company fails any continued listing standard during the monitor period, the Company will not be permitted to submit a compliance plan or receive a cure or compliance period, and Nasdaq will promptly issue a Staff Delisting Determination, which the Company would be entitled to appeal to a Hearings Panel.

Additional information regarding the Panel's decision and the investor agreements is set forth in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 5, 2026.

About SCWorx Corp.

SCWorx provides data management solutions to healthcare providers. The Company's solutions are designed to improve the accuracy, standardization and utilization of healthcare supply-chain data and support healthcare organizations in managing their item master and related supply-chain information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the reinstatement of trading in the Company's common stock on The Nasdaq Capital Market and the timing thereof, the Company's ability to maintain compliance with Nasdaq's continued listing requirements and the conditions of the Panel's decision, and the potential exercise by the private placement investors of their termination rights. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that Nasdaq delays or does not reinstate trading in the Company's common stock, the risk that the Nasdaq Listing and Hearing Review Council calls the Panel's decision for review and modifies or reverses it, the risk that the Company fails to satisfy a Nasdaq continued listing standard during the Panel Monitor period, in which case the Company would not be afforded a compliance plan or cure period, the risk that the private placement investors exercise their termination rights, and the other risks described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Contact

SCWorx Investor Relations

ir@scworx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Nasdaq approve SCWorx’s continued listing?

The Hearings Panel determined that SCWorx met Nasdaq’s continued listing requirements, including minimum bid price and publicly held shares. Publicly held shares reached 549,092 as of September 17, 2026, above the 500,000-share minimum. Closing bids were at least $1.00 every trading day since August 4, including the required 10 consecutive trading days following September 17.

When will SCWorx WORX shares resume trading on Nasdaq?

Nasdaq trading will resume on a date to be scheduled by Nasdaq. SCWorx is submitting the reinstatement form on October 5, 2026, and expects to announce the date once Nasdaq confirms it. Until reinstatement, shares continue to be quoted on OTCQB under WORX.

Can SCWorx appeal a delisting determination during its Nasdaq monitoring period?

SCWorx would be entitled to appeal to a Hearings Panel if Nasdaq issues a Staff Delisting Determination during the monitoring period. If Nasdaq determines that any continued listing standard has been breached, it will promptly issue that determination without allowing a compliance plan or cure or compliance period.